Monthly Archives: February 2017

Ultimate Night Cream Skin Type Matched With Retinol & Vitamin C Launched

A new website has been launched by Best Night Cream, an online guide to night creams. This new site guides the reader through different types of night cream and their benefits and also discusses the best ones to buy.

Ultimate Night Cream Skin Type Matched With Retinol & Vitamin C Launched

San Antonio, United States – February 24, 2017 /PressCable/

Best Night Cream has launched a new website. Best Night Cream is a site that helps readers understand why they need a night cream, how to pick the right one for their skin type and looks at some of the best available to buy.

For more information please visit: http://www.bestnightcream.com.

Best Night Cream has been launched to help people navigate the sometimes confusing world of night time skin care. The site explains that engaging in a proper skin care routine is imperative for improving the look and feel of the skin. It goes on to state that a good nights sleep is important and pairing this with a good night cream can really boost skin condition.

It starts by guiding the reader through the different types of night cream. The first is anti aging creams to help improve wrinkles, sagging and discoloration and commonly contain Retinol. Retinol is a form of vitamin A and can help to minimize fine lines and pores.

Other types of night cream are aimed at oily skin and acne prone skin. Oily skin is caused by excess sebum and tends to display less wrinkles but still needs nourishing with a night cream containing ingredients such as anti inflammatory nicotinamide.

Acne prone skin also needs nourishing and common ingredients in acne night creams include benzoyl peroxide, sulfur, vitamin C and salicylic acid, which gently exfoliates the skin through a chemical action.

The site goes on to explain how to use night creams and what results to expect. Once the user has determined their skin type and purchased the right cream for them they should then start using the cream nightly. The site explains that with regular use and a good sleeping regime, results may be seen in as little as two weeks, but on average it will take three to four.

Best Night Cream have also put some night creams through their paces and have published their results on the website. They test the benefits of the creams and then list the pros and cons of the cream so their readers can make an informed choice.

Those wishing to find out more can visit the website on the link provided above.

Contact Info:
Name: Beth Atkins
Organization: Best Night Cream
Address: 901 Northeast Interstate 410 Loop, San Antonio, Texas 78209, United States

For more information, please visit http://www.bestnightcream.com/

Source: PressCable

Release ID: 173026

DunnTek Reveals SEO Project Management Secrets

DunnTek’s new series reveals insider secrets to successful SEO project management and solves some of the problems inherent in traditional approaches.

Apex, NC, United States – February 24, 2017 /PressCable/

Raleigh SEO company DunnTek has revealed a number of insider considerations with SEO project management that both small business owners and newcomers to Search Engine Optimization alike may benefit from knowing in order to avoid some common problems. In the series, company owner Brian Dunn, an industry-certified project management professional, begins by explaining a bit about what project management is, as well as what it isn’t. This may ruffle a few feathers since the term project management is frequently used to describe things that, it turns out, the project management industry may not consider projects at all.

“If you have a standardized service in which you’re following an existing business process to deliver basically the same thing each time, that may not be considered a project according to the technical definition of what constitutes a project,” Dunn says. He continues, “Because of that, search engine optimization may or may not be a project depending on the situation and the approach being taken by the agency.”

Within the SEO industry, some companies focus on customized services designed around each individual customer’s unique situation, while others focus on selling standardized services that may be essentially the same for any customer that buys them. The classic approach to project management that many people will be familiar with, which involves mapping the different steps of the project out in advance, may lack the flexibility required for search engine optimization in the current climate, and more modern iterative approaches to project management may be needed due to the highly competitive nature of SEO in certain industries as well as a much greater frequency of changes in the ranking algorithms of search engines. Such approaches are based around the idea that, rather than trying to plan every detail in advance, results will be achieved through a series of progressive cycles that build on each other as achievements and next steps are constantly monitored and re-assessed.

In his series about SEO project management, available at http://dunntek.com/seo/projectmanagement, Dunn dispels some common myths while revealing some of the nuances that can help SEO projects run more smoothly. On the subject of project communication, for example, he explains why too much detail may create more problems than it solves. He goes on to say that the purchase of custom SEO services has something in common with buying something to eat from a restaurant with a secret recipe. “You can buy the chicken, and it’s going to be one mighty good piece of chicken. What you can’t buy is the recipe,” Dunn says.

More information about custom SEO solution is available on the DunnTek website at http://dunntek.com/seo

Contact Info:
Name: Brian Dunn
Organization: DunnTek
Address: 5448 Apex Peakway #370, Apex, NC 27502, United States
Phone: +1-919-589-2535

For more information, please visit http://dunntek.com

Source: PressCable

Release ID: 173051

Self-contained breathing apparatus (SCBA) Market Consumption by Type, Application And Sales 2017 Analysis And Forecasts To 2022

focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer

Pune, India – February 24, 2017 /MarketersMedia/

Self-contained breathing apparatus (SCBA) Industry

Description

Wiseguyreports.Com Adds “Self-contained breathing apparatus (SCBA) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2022” To Its Research Database

This report studies Self-contained breathing apparatus (SCBA) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering

ResMed
Philips Respironics
Covidien
Fisher and Paykel Healthcare
Maquet
CareFusion Corporation
Teleflex
DeVilbiss Healthcare(Drive Medical)
Invacare
Drager USA

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/996041-global-self-contained-breathing-apparatus-scba-market-research-report-2017

Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Self-contained breathing apparatus (SCBA) in these regions, from 2011 to 2021 (forecast), like

North America
Europe
China
Japan
Southeast Asia
India

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into
Oxygen Respirator
Air Respirator
Chemical Oxygen Respirator

Split by application, this report focuses on consumption, market share and growth rate of Self-contained breathing apparatus (SCBA) in each application, can be divided into
Oil?and?Gas?
Industrial
Pharmaceutical?&?Healthcare
Others

Leave a Query @ https://www.wiseguyreports.com/enquiry/996041-global-self-contained-breathing-apparatus-scba-market-research-report-2017

Table of Contents

Global Self-contained breathing apparatus (SCBA) Market Research Report 2017
1 Self-contained breathing apparatus (SCBA) Market Overview
1.1 Product Overview and Scope of Self-contained breathing apparatus (SCBA)
1.2 Self-contained breathing apparatus (SCBA) Segment by Type
1.2.1 Global Production Market Share of Self-contained breathing apparatus (SCBA) by Type in 2015
1.2.2 Oxygen Respirator
1.2.3 Air Respirator
1.2.4 Chemical Oxygen Respirator
1.3 Self-contained breathing apparatus (SCBA) Segment by Application
1.3.1 Self-contained breathing apparatus (SCBA) Consumption Market Share by Application in 2015
1.3.2 Oil?and?Gas?
1.3.3 Industrial
1.3.4 Pharmaceutical?&?Healthcare
1.3.5 Others
1.4 Self-contained breathing apparatus (SCBA) Market by Region
1.4.1 North America Status and Prospect (2012-2022)
1.4.2 Europe Status and Prospect (2012-2022)
1.4.3 China Status and Prospect (2012-2022)
1.4.4 Japan Status and Prospect (2012-2022)
1.4.5 Southeast Asia Status and Prospect (2012-2022)
1.4.6 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Self-contained breathing apparatus (SCBA) (2012-2022)

….

7 Global Self-contained breathing apparatus (SCBA) Manufacturers Profiles/Analysis
7.1 ResMed
7.1.1 Company Basic Information, Manufacturing Base and Its Competitors
7.1.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.1.2.1 Oxygen Respirator
7.1.2.2 Air Respirator
7.1.3 ResMed Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.1.4 Main Business/Business Overview
7.2 Philips Respironics
7.2.1 Company Basic Information, Manufacturing Base and Its Competitors
7.2.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.2.2.1 Oxygen Respirator
7.2.2.2 Air Respirator
7.2.3 Philips Respironics Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.2.4 Main Business/Business Overview
7.3 Covidien
7.3.1 Company Basic Information, Manufacturing Base and Its Competitors
7.3.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.3.2.1 Oxygen Respirator
7.3.2.2 Air Respirator
7.3.3 Covidien Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.3.4 Main Business/Business Overview
7.4 Fisher and Paykel Healthcare
7.4.1 Company Basic Information, Manufacturing Base and Its Competitors
7.4.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.4.2.1 Oxygen Respirator
7.4.2.2 Air Respirator
7.4.3 Fisher and Paykel Healthcare Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.4.4 Main Business/Business Overview
7.5 Maquet
7.5.1 Company Basic Information, Manufacturing Base and Its Competitors
7.5.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.5.2.1 Oxygen Respirator
7.5.2.2 Air Respirator
7.5.3 Maquet Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.5.4 Main Business/Business Overview
7.6 CareFusion Corporation
7.6.1 Company Basic Information, Manufacturing Base and Its Competitors
7.6.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.6.2.1 Oxygen Respirator
7.6.2.2 Air Respirator
7.6.3 CareFusion Corporation Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.6.4 Main Business/Business Overview
7.7 Teleflex
7.7.1 Company Basic Information, Manufacturing Base and Its Competitors
7.7.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.7.2.1 Oxygen Respirator
7.7.2.2 Air Respirator
7.7.3 Teleflex Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.7.4 Main Business/Business Overview
7.8 DeVilbiss Healthcare(Drive Medical)
7.8.1 Company Basic Information, Manufacturing Base and Its Competitors
7.8.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.8.2.1 Oxygen Respirator
7.8.2.2 Air Respirator
7.8.3 DeVilbiss Healthcare(Drive Medical) Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.8.4 Main Business/Business Overview
7.9 Invacare
7.9.1 Company Basic Information, Manufacturing Base and Its Competitors
7.9.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.9.2.1 Oxygen Respirator
7.9.2.2 Air Respirator
7.9.3 Invacare Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.9.4 Main Business/Business Overview
7.10 Drager USA
7.10.1 Company Basic Information, Manufacturing Base and Its Competitors
7.10.2 Self-contained breathing apparatus (SCBA) Product Type, Application and Specification
7.10.2.1 Oxygen Respirator
7.10.2.2 Air Respirator
7.10.3 Drager USA Self-contained breathing apparatus (SCBA) Production, Revenue, Price and Gross Margin (2015 and 2016)
7.10.4 Main Business/Business Overview

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=996041

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Contact Info:
Name: NORAH TRENT
Email: Sales@Wiseguyreports.Com
Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD
Address: Pune -40027, Maharashtra, India
Phone: +91 841 198 5042

Source URL: http://marketersmedia.com/self-contained-breathing-apparatus-scba-market-consumption-by-type-application-and-sales-2017-analysis-and-forecasts-to-2022/173023

For more information, please visit https://www.wiseguyreports.com/sample-request/996041-global-self-contained-breathing-apparatus-scba-market-research-report-2017

Source: MarketersMedia

Release ID: 173023

Oklahoma City Edmond Yard Drainage Experts Say To Prepare Now For Rainy Season

Bill’s Custom Concrete & Yard Drainage tells homeowners in the Oklahoma City Metro area that now is the time to be thinking about yard drainage issues and solving any potential problems you may have before the spring rainy season.

Oklahoma City Edmond Yard Drainage Experts Say To Prepare Now For Rainy Season

Oklahoma City, United States – February 24, 2017 /PressCable/

The premier Oklahoma City yard drainage experts Bill’s Custom Concrete & Yard Drainage say that now is the perfect time to prepare for potential spring flooding. Many homeowners do not think about yard drainage problems until it’s too late and they have already been flooded. Many homeowners in the Oklahoma City Metro were caught by surprise in the floods in May and June of 2015, and their property experienced damage as a result.

More information is available at http://billscustomconcrete.com/services/yard-drainage-systems/.

Bill’s Custom Concrete & Yard Drainage is Oklahoma City’s most established and respected yard drainage experts currently celebrating 41 years of industry leading drainage solutions for home owners. During this time Bill’s Custom Concrete & Yard Drainage has solved many drainage problems that could be as simple as adding proper guttering to the home to installing new French drains or surface drains to take care of excess water run off from heavy rains. During this time Bill’s has provided yard drainage solutions for home owners in Oklahoma City, Edmond, Moore, Norman, Midwest City, Yukon, Mustang and the greater OKC Metro area.

Bill’s recently received a positive review on Google for a potential customer that had called the office after the 2015 Oklahoma City floods where Bill Guinn helped the person determine the cause of their flooding without actually installing new drainage systems for them. Part of the review quoted ” Bill saved our condo association about $10k by looking at all the possible issues for the flooding. Bill is a very honest and professional yard drainage expert and you should call Bill’s Custom Concrete & Yard Drainage if your property has had issues with flooding in the past.” Bill’s has many reviews on Google, Yelp, Facebook, Better Business Bureau and many other review sites around the Internet, and Bill always encourages potential customers to read the reviews of other satisfied customers they have had over the years.

Bill Guinn stresses the importance of proper yard drainage systems that can not only help with avoiding flooding of the home but also prevent foundation problems and standing water issues. With the recent concerns with the West Nile Virus and the Zika Virus, Bill says “It is important to avoid standing water in your yard or near your home for the safety of your home and foundation, but it could also be a health issue to avoid having breeding areas for mosquitoes after heavy rains.”

Free estimates and consultations with Bill’s Custom Concrete & Yard Drainage can be requested at 405 755 3975 or through the website link above with multiple photo galleries, videos and examples of its yard drainage solutions for homeowners in the Oklahoma City Metro area.

Contact Info:
Name: Bill Guinn
Organization: Bill’s Custom Concrete & Yard Drainage
Address: 14609 Remington Way, Oklahoma City 73134, United States

For more information, please visit http://billscustomconcrete.com

Source: PressCable

Release ID: 173028

Littleton Denver Laser Tattoo Removal Clinic Featured In D’Inked Documentary

The popular Denver laser tattoo removal clinic Rethink The Ink, providing free consultations and custom treatment plan quotes at 800-677-8435, will feature in the highly anticipated ‘D’Inked’ documentary making its debut at the Los Angeles Film School on March 2nd, 2017, at 7 pm.

Littleton Denver Laser Tattoo Removal Clinic Featured In D’Inked Documentary

Littleton, United States – February 24, 2017 /PressCable/

The popular and industry leading Denver, Colorado laser tattoo removal clinic Rethink The Ink will feature in the highly anticipated ‘D’Inked’ documentary film making its debut at the Los Angeles Film School on March 2nd, 2017.

More information is available at http://rethinktheinklasertattooremoval.com.

The Rethink The Ink is an acclaimed, certified and industry leading laser tattoo removal clinic based in Littleton, Colorado, with extensive experience and established reputation providing the most reliable, safe, effective and affordable tattoo removal treatments for clients in Denver and the surrounding areas.

The popular laser tattoo removal clinic who earned its industry leading reputation by combining a team of renowned and certified laser tattoo removal technicians, the most advanced q-switch laser tattoo removal methods and the most customized treatment plans to safely and effectively remove tattoos of any size and color, will feature in the highly anticipated ‘D’Inked’ documentary.

Due to its expertise and reputation in the industry, The Rethink The Ink clinic was sought out to play a key role in the tattoo removal treatment and process of Jacob Tillman, whose tattoo removal journey the documentary follows. The highly anticipated film about people who have tattoo, the ones who do them and the ones who make them disappear is making its debut at the Los Angeles Film School on March 2nd, 2017, at 7 pm.

Free consultations and completely personalized no-obligation pricing and treatment plans to suit each client’s individual removal needs can be requested and scheduled at 800-677-8435 or through the website link provided above along with more on Rethink The Ink’s ‘Quanta Q Plus C “Top Hat Profile” removal process and its leading reputation or proven track record, including multiple client testimonials and extensive ‘before and after photo’ galleries.

The Rethink The Ink clinic explains that “we are a leader in tattoo removal mostly because we pride ourselves on three essential elements that keep setting us apart from our competition: technology, technique and training. Due to our expertise, we were sought out to help with the documentary film ‘D’Inked’ and our goal was to provide an entertaining and informative resource to everyone who is interested in the culture of tattoos and the possibilities of tattoo removal.”

Contact Info:
Name: Victor Beyer
Email: victor@rethinktheinklasertattooremoval.com
Organization: Rethink The Ink
Address: 26 W Dry Creek Cir #730, Littleton, CO 80120, United States
Phone: +1-720-230-7270

For more information, please visit http://www.rethinktheinklasertattooremoval.com

Source: PressCable

Release ID: 173034

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BT Group plc of Class Action Lawsuit and Upcoming Deadline – BT

NEW YORK, NY / ACCESSWIRE / February 24, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against BT Group plc (“BT Group” or the “Company”) (NYSE: BT) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-00558, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired BT Group American Depositary Receipts (“ADRs”) between May 23, 2013 and January 23, 2017, inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased BT Group securities during the Class Period, you have until March 27, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

BT Group is a multinational telecommunications services company that offers fixed-line services, broadband, mobile and TV products and services, and networked IT services in the United Kingdom and across the world. The Company also sells wholesale products and services to communications providers around the world. Globally, BT Group supplies managed networked IT services to multinational corporations, domestic businesses, and national and local government organizations.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s Italian division had for years engaged in improper accounting practices; (ii) as a result, BT Group significantly overstated its earnings throughout the Class Period; (iii) the foregoing facts, when they became known, would foreseeably cause BT Group to cut its revenue, earnings, and free cash flow forecasts; and (iv) as a result of the foregoing, BT Group’s public statements were materially false and misleading at all relevant times.

On October 27, 2016, BT Group announced that the Company had uncovered “inappropriate management behavior” at its Italian division. BT Group advised investors that the Company had “conducted an initial internal investigation” which “included a review of accounting practices during which we have identified certain historical accounting errors and reassessed certain areas of management judgment.” Consequently, the Company announced that it had “written down the value of items on the balance sheet by £145 [million].” On this news, BT Group’s ADR price fell $0.57, or 2.39%, to close at $23.25 on October 27, 2016.

On January 24, 2017, BT Group issued a news release entitled, “Update on investigation into BT’s Italian business and on BT Group outlook.” On this news, BT Group’s ADR price fell $5.05, or 20.67%, to close at $19.38 on January 24, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 455968

Axiom cares Acknowledges Board member wins Person of the Year

Axiom cares a 501(c)3, would like to congratulate Board member Christin Collins for being named the Person of the Year in 2016, by The Fort Myers News-Press.

Axiom cares Acknowledges Board member wins Person of the Year

Fort Myers, United States – February 24, 2017 /PressCable/

FOR IMMEDIATE RELEASE :

Ft. Myers, Florida – (February 22, 2017) – Axiom cares a 501(c)3 is proud to announce Board member Christin Collins, System Health and Wellness Strategic Business Partner at Lee Memorial Health System, has been named the Person of the Year in 2016 by The Fort Myers News-Press. The People Of the Year Awards Breakfast was held on Tuesday February 21st, 8-10:30am in the Cohen Center Ballroom on the FGCU campus.

In her leadership roles with the Lee Health and Lee Heath Foundation, Christin has partnered to raise millions of dollars for The Golisano Children’s Hospital of Southwest Florida. Volunteered her time as board member for the PACE Center for Girls, founding the Love that Dress! fundraiser, she is currently Co-Chairing the Southwest Florida Wine and Food Festival among many other leadership roles in the local community

“I’m very passionate about aligning people with their generosity with causes that they’re passionate about. That’s very fulfilling for me,” Collins said. “And working on what I feel is the biggest project I’ll see in my lifetime — the building of a children’s hospital — was very euphoric.”

Axiom cares would also like to acknowledge another board member, Samira Beckwith, who has previously won Person Of The Year in 2010. Samira K. Beckwith has served as President and CEO of Hope Healthcare for more than 25 years. With her leadership, the organization grew from a hospice caring for fewer than 100 patients a day, to a comprehensive home health care system. Today, Hope cares for more than 4,000 individuals a day through a variety of innovative programs.

Cole Peacock: “It is truly amazing to witness the passion and leadership Christin displays on a daily basis, she is an incredible role model for the future leaders of the community. Having Samira and Christin as Person of the Year speaks to the strength of our Board and the positive impact in the local community. Congratulations to both of these matriarchs of SWFL.”

About Axiom cares:

Axiom cares a 501(c)3 dedicated to providing proper ‘Medical Nutrition’, education, and partnerships to individuals, families and loved ones in need.

Mission: To facilitate and conduct scientific research into areas of unmet global medical nutritional needs while also providing education and assistance to those in need of medical nutrition without the financial resources of obtaining it on their own.

#30#

Contacts:

Cole Peacock, Axiom cares (888) 444-7992

Contact Info:
Name: Cole Peacock
Email: contact@axiombiopharma.com
Organization: Axiom cares
Address: 1591 Hayley Lane, Fort Myers, FL 33907, United States
Phone: +1-888-444-7992

For more information, please visit https://www.Axiomcares.org

Source: PressCable

Release ID: 172329

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in DaVita Inc. of Class Action Lawsuit and Upcoming Deadline – DVA

NEW YORK, NY / ACCESSWIRE / February 24, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA) and certain of its officers. The class action, filed in United States District Court, District of Colorado, is on behalf of a class consisting of investors who purchased or otherwise acquired DaVita securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased DaVita securities between August 5, 2015 and October 21, 2016, both dates inclusive, you have until April 3, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end-stage renal disease (“ESRD”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) the Company was using AKF as a vehicle to facilitate these improper practices; (3) as a result, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result of the foregoing, DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On August 18, 2016, The Centers for Medicare & Medicaid Services (“CMS”) issued a public request for information regarding alleged steering of Medicare and Medicaid beneficiaries into other plans in order to earn higher reimbursement rates. As part of this request, CMS sent letters to all Medicare-enrolled dialysis centers (including DaVita) informing them of its announcement.

In reaction to the disclosure about the CMS inquiry into the industry and the potential rule changes, DaVita’s stock price dropped $3.17 per share, or 4.69%, on unusually heavy trading volume from $67.65 per share on August 18, 2016 to $64.48 per share on August 19, 2016.

On Sunday, October 23, 2016, the St. Louis Post published an article entitled, “DaVita encouraged some low-income patients to enroll in commercial plans” that accused DaVita directly of steering clients to private insurers and utilizing its own money to pay for health insurance premiums through the AKF.

In reaction to the disclosures in the St. Louis Post article, DaVita’s stock price dropped $2.86 per share, or another 4.69%, from $60.96 per share on Friday, October 21, 2016 to $58.10 per share on Monday, October 24, 2016.

On October 31, 2016, DaVita issued a press release announcing that it was suspending support for applications to the AKF for charitable premium assistance by patients enrolled in minimum essential Medicaid coverage effective immediately.

Then, on January 6, 2017, The Wall Street Journal reported that investigators from the U.S. Department of Justice “are probing a controversial arrangement under which kidney-care companies support charitable efforts to help patients pay health-insurance premiums, according to disclosures from major dialysis providers.” As part of the investigation, the U.S. Attorney’s Office for the District of Massachusetts had subpoenaed DaVita and the AKF seeking information relating to its charitable premium assistance.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 455970

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Psychemedics Corporation of Class Action Lawsuit and Upcoming Deadline – PMD

NEW YORK, NY / ACCESSWIRE / February 24, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ: PMD) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, is on behalf of a class consisting of investors who purchased or otherwise acquired Psychemedics securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, both dates inclusive, you have until April 3, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

Psychemedics Corporation provides patented, FDA-cleared services for the detection of drug abuse through the analysis of hair samples. The Company’s tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) through its affiliate Psychemedics Brasil Exames Toxicológicos Ltda. (“Psychemedics Brasil”), the Company engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (ii) in turn, Psychemedics lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, Psychemedics’ public statements were materially false and misleading at all relevant times.

On January 31, 2017, Bloomberg reported that a Brazilian judge had ordered Psychemedics’ local representative in Brazil, Psychemedics Brasil, to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for the purpose of “preventing other companies from accessing (the) market,” an indemnification that may cost the Company millions of dollars. The Bloomberg article further reported that Psychemedics Brasil may be further investigated by Brazil’s Administrative Council for Economic Defense for engaging in “cartel practices” in an attempt to form a drug testing monopoly.

Psychemedics issued a press release in response to the Brazilian court order denying involvement in the lawsuit, stating that “Psychemedics Brasil has been a distributor of Psychemedics Corporation’s hair testing services for more than fifteen years” and that it expects their business in Brazil to “continue as usual.”

On this news, Psychemedics’ share price fell $6.75, or 26.35%, to close at $18.87 on January 31, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 455974

Hemophilia A and B Asia-Pacific market Forecast To Increase $699.1 and $112.9 Million Respectively in 2022 from $444.9m and $76.3m in 2015

The Hemophilia A and B Asia-Pacific market will be valued at $699.1m and $112.9m respectively in 2022, growing from $444.9m and $76.3m in 2015, at compound annual growth rates of 6.7% and 5.8%.Various drivers and barriers will influence the market over the forecast period.

Pune, India – February 24, 2017 /MarketersMedia/

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy The Hemophilia A and B Asia-Pacific market will be valued at $699.1m and $112.9m respectively in 2022, growing from $444.9m and $76.3m in 2015, at compound annual growth rates of 6.7% and 5.8%.

Complete report on Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 spread across 126 pages is available at http://www.reportsnreports.com/reports/767636-hemophilia-a-and-b-therapeutics-in-asia-pacific-markets-to-2022-growth-driven-by-increasing-treatment-receiving-pool-launch-of-long-acting-replacement-therapies-and-non-factor-therapy.html

The current marketed products landscape comprises replacement factor therapies, such as recombinant therapies and new long-acting recombinant products. The current pipeline shows strong promise, as it shows a gradual shift from short-acting recombinant factor VIII or factor IX to long-acting recombinant factor VIII, and from factor replacement therapies to non-factor therapies. Nevertheless, significant unmet need remains for products that can avoid the development of inhibitors in patients with hemophilia.

List of Tables:
• Hemophilia A Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
• Hemophilia B Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
• Hemophilia A Therapeutics Market, India, Market Forecast, 2015-2022
• Hemophilia B Therapeutics Market, India, Market Forecast, 2015-2022
• Hemophilia A Therapeutics Market, China, Market Forecast, 2015-2022
• Hemophilia B Therapeutics Market, China, Market Forecast, 2015-2022
• Hemophilia A Therapeutics Market, Australia, Market Forecast, 2015-2022
• Hemophilia B Therapeutics Market, Australia, Market Forecast, 2015-2022
• Hemophilia A Therapeutics Market, South Korea, Market Forecast, 2015-2022
• Hemophilia B Therapeutics Market, South Korea, Market Forecast, 2015-2022
• Hemophilia A Therapeutics Market, Japan, Market Forecast, 2015-2022
• Hemophilia B Therapeutics Market, Japan, Market Forecast, 2015-2022
• Hemophilia A and B Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
• Hemophilia A and B Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
• Hemophilia A and B Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Treatment of Hemophilia A and B

Request Sample
http://www.reportsnreports.com/contacts/discount.aspx?name=767636

Scope:
The Hemophilia A and B Asia-Pacific market will be valued at $699.1m and $112.9m respectively in 2022, growing from $444.9m and $76.3m in 2015, at compound annual growth rates of 6.7% and 5.8%.
• How will non-factor therapies contribute to the growth?
• What will be the impact of the new long-acting recombinant factor VIII and recombinant factor IX products in the hemophilia A and B market sales?

The pipeline contains a range of molecule types and molecular targets, including both those that are well established in hemophilia A and B, and novel targeted therapies.
• Which molecular targets appear most frequently in the pipeline?
• Will the pipeline address unmet needs such as less frequently administered therapies and risk of inhibitor development for hemophilia A and B patients?
• What are the most promising first-in-class targets for hemophilia A and B?
• Will the current first-in-class targets have a broader therapeutic potential across the Asia-Pacific markets?

Various drivers and barriers will influence the market over the forecast period.
• What are the barriers that will limit the uptake of premium-priced recombinant factor VIII and recombinant factor IX therapies in the assessed countries?
• Which factors are most likely to drive the market in these countries?

Co-development deals are the most common form of strategic alliance in hemophilia A and B, with total deal values ranging from under $10m to over $280m.
• How do deal frequency and value compare between target families and molecule types?
• What were the terms and conditions of key co-development deals?

Get this Report: http://www.reportsnreports.com/purchase.aspx?name=767636

Reasons to buy:
• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
• Visualize the composition of the hemophilia A and B market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
• Analyze the hemophilia A and B pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating hemophilia A and B.
• Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
• Predict hemophilia A and B market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
• Identify commercial opportunities in the hemophilia A and B deals landscape by analyzing trends in licensing and co-development deals

About Us:
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsandreports.com
Organization: ReportsandReports
Address: Pune
Phone: + 1 888 391 5441

Source URL: http://marketersmedia.com/hemophilia-a-and-b-asia-pacific-market-forecast-to-increase-699-1-and-112-9-million-respectively-in-2022-from-444-9m-and-76-3m-in-2015/172517

For more information, please visit http://www.reportsnreports.com/reports/767636-hemophilia-a-and-b-therapeutics-in-asia-pacific-markets-to-2022-growth-driven-by-increasing-treatment-receiving-pool-launch-of-long-acting-replacement-therapies-and-non-factor-therapy.html

Source: MarketersMedia

Release ID: 172517